Leonard JD - Tarsus Pharmaceuticals Chief Officer
| TARS Stock | USD 48.24 1.84 3.97% |
Insider
Leonard JD is Chief Officer of Tarsus Pharmaceuticals
| Age | 48 |
| Address | 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 |
| Phone | 949 409 1801 |
| Web | https://www.tarsusrx.com |
Tarsus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2726) % which means that it has lost $0.2726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5956) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1.6 M in 2024, whereas Total Assets are likely to drop slightly above 165.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kory CPA | Entrada Therapeutics | 45 | |
| Jennifer Cormier | PepGen | N/A | |
| Darlene Noci | Nuvalent | 46 | |
| Michael Gerometta | Opthea | 59 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| JeanChristophe Marcoux | Genfit | 46 | |
| Sonia DPHIL | PepGen | 38 | |
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| FACC MD | Stoke Therapeutics | 61 | |
| David Hanley | Nuvation Bio | 54 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Thomas Baetz | Genfit | 49 | |
| Lynn Scherm | Tyra Biosciences | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| MD MBA | Opthea | N/A | |
| Nathan Dowden | Entrada Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.27 |
Tarsus Pharmaceuticals Leadership Team
Elected by the shareholders, the Tarsus Pharmaceuticals' board of directors comprises two types of representatives: Tarsus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tarsus. The board's role is to monitor Tarsus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Tarsus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tarsus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Farrow, CFO Officer | ||
| Leonard JD, Chief Officer | ||
| Scott Youmans, Vice Sales | ||
| Seshadri Neervannan, Chief Officer | ||
| Adrienne Kemp, Senior Communications | ||
| Elizabeth MD, Chief Director | ||
| Aziz MBA, Chief Officer | ||
| David Nakasone, Head Relations | ||
| Matthew MBA, Vice Marketing | ||
| Michael Ackermann, CoFounder Board | ||
| Jeffrey CPA, CFO Officer | ||
| Bobak MD, President, CoFounder | ||
| Dianne MSW, Chief Officer | ||
| Cara Miller, Senior Affairs | ||
| MD JD, General Secretary |
Tarsus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tarsus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (0.52) % | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 38.23 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Shares Owned By Institutions | 91.30 % | ||||
| Number Of Shares Shorted | 8.16 M | ||||
| Price To Book | 7.76 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.